Shire Granted EU Marketing Authorization of Onivyde in Combination With 5-Fluorouracil and Leucovorin for Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy